|First Author, Year (Ref. #)||Imaging Used||Sample Size||Patient Population||Main Findings|
|Kaneda et al., 2007 (65)||IVUS||N = 525|
|Patients receiving BMS and undergoing IVUS at 6–8 months post-stent implantation.||Greater neointimal hyperplasia in women compared with men due to smaller stent area. When adjusted for stent area, these differences were lost.|
|Nakatani et al., 2011 (66)||IVUS||ZES: N = 391 (28.1% women);|
BMS: N = 85 (21.1% women)
|ZES group: Stable and unstable angina patients enrolled in ENDEAVOR II, ENDEAVOR II Continued Access Registry, ENDEAVOR III, and ENDEAVOR IV (Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System) studies who were treated with ZES and had IVUS at 8-month follow-up.|
BMS group: Control subjects were patients in the ENDEAVOR II trial treated with BMS who had IVUS at 8-month follow-up.
|Female sex was associated with less neointimal obstruction on IVUS at 8 months in the ZES but not BMS group.|
|Regueiro et al., 2015 (3) (EXAMINATION trial)||IVUS||N = 1,498|
|Patients with STEMI undergoing PCI randomized to be treated with EES or BMS.||Women demonstrated lower risk of restenosis (HR: 0.55; 95% CI: 0.32–0.95) compared with men, driven by better performance of EES in women.|
BMS = bare-metal stent(s); EES = everolimus-eluting stent(s); ZES = zotarolimus-eluting stent(s); other abbreviations as in Tables 2 and 3.